Breakthrough FDA Approval Offers First-Ever Treatment for Life-Threatening Mitochondrial Energy Disorder

The U.S. Food and Drug Administration has approved UCB's Kygevvi, marking a historic milestone for patients with thymidine kinase 2 deficiency (TK2d), an ultra-rare inherited mitochondrial disorder that has lacked…

Continue Reading Breakthrough FDA Approval Offers First-Ever Treatment for Life-Threatening Mitochondrial Energy Disorder